United Kingdom Daily Briefing

The Financial Times reported Monday that Alphabet is selling up to $80 billion in shares specifically to fund its AI infrastructure build-out, a capital raise that dwarfs most sovereign debt offerings. For UK investors, the transmission is via index exposure to US mega-cap tech through global funds and the Sterling-dollar basis: a $80B equity offer from Alphabet could create short-term downward price pressure on GOOG/GOOGL, which flows through to UK-domiciled global equity tracker funds. The scale of the AI capex commitment also validates the infrastructure-hardware names (HPE, NVDA) that surged in the US session.

AstraZeneca dropped 3.2% to $179.71 and GSK fell 2.4% to $49.31 Monday, with no specific company-level news apparent — the move looks like sector-level pharma rotation out of defensive healthcare and into energy and enterprise tech globally. Both stocks are among the heaviest weights in the FTSE 100 by market cap, meaning their combined decline cost the index roughly 40-50 basis points of performance. For dividend-focused UK investors, the AZN yield increases as the share price falls — AZN's current yield approaching 2.5% may attract value buyers if there's no fundamental news driving the drop.

Live Mint reported on Goldman Sachs' senior investment banking observation that AI data center mandates are now consuming the attention of Goldman's top dealmakers, crowding out other sector coverage. The data point matters for UK M&A practitioners: it means the London-based advisory community faces competition for senior banker talent from AI-infrastructure deal flow concentrated in the US. For UK-listed engineering and construction names with data center capabilities (Balfour Beatty, Laing O'Rourke privately), this is a long-duration capex theme that justifies premium order book valuations.